enzh-TWfrdeitjaptrues

This is where we will be posting upcoming events of note.  Please return to this page as we intend to update on a regular basis.

Latest Bing Center News

Lu Kleppinger: Therapy Round Two- Ibrutinib, the Freedom of a Pill!

Lu Kleppinger: Therapy Round Two- Ibrutinib, the Freedom of a Pill!

After undergoing eighteen months of chemotherapy ending in 2014, which resulted in much success and years of being well managed and free of infusions, my WM flared up again, significantly, in 2019.  This required me to go back into treatment.

Read more..

WM and COVID-19: WMUK Webinar Recordings

WM and COVID-19: WMUK Webinar Recordings

On Friday 19 June, over 260 people joined our webinar, in partnership with Lymphoma Action, to hear our panel of UK experts answer some of the most commonly asked questions around COVID-19 and Waldenstrom's macroglobulinaemia (WM).

Read more..

Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM

Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM

Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.

Read more..

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application ...

Read more..

COVID-19 & Hematologic Malignancies: Patient Experience Update

COVID-19 & Hematologic Malignancies: Patient Experience Update

We are excited to announce this new webcast focusing on the experience of patients undergoing treatment for hematologic malignancies during the COVID-19 era.

Read more..

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.

Read more..

BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia

BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia

In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.

Read more..

ASCO 2020 Virtual Meeting

ASCO 2020 Virtual Meeting

ASCO (American Society of Clinical Oncologists) will hold their 2020 conference online.  As in the past, they provide abstracts online via the conference website.  The scientific program will take place May 29 through May 31.

Read more..

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.

Read more..

COVID-19 Information for Our Patients

COVID-19 Information for Our Patients

The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.

Read more..